Land: Europeiska unionen
Språk: engelska
Källa: EMA (European Medicines Agency)
sotorasib
Amgen Europe BV
L01XX73
sotorasib
Antineoplastic agents
Carcinoma, Non-Small-Cell Lung
Lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy.
Revision: 2
Authorised
2022-01-06
30 B. PACKAGE LEAFLET 31 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT LUMYKRAS 120 MG FILM-COATED TABLETS sotorasib This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What LUMYKRAS is and what it is used for 2. What you need to know before you take LUMYKRAS 3. How to take LUMYKRAS 4. Possible side effects 5. How to store LUMYKRAS 6. Contents of the pack and other information 1. WHAT LUMYKRAS IS AND WHAT IT IS USED FOR LUMYKRAS contains the active substance sotorasib and belongs to a group of medicines known as antineoplastic agents (cancer medicines). LUMYKRAS is used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC) when it is advanced and has spread to other parts of the body. LUMYKRAS is used when previous treatments were not effective in stopping the growth of the cancer, and when the cancer cells have a genetic change that allows them to produce an abnormal form of protein called _KRAS G12C_ . Your doctor will test your cancer cells for this change beforehand to make sure that LUMYKRAS is right for you. HOW DOES LUMYKRAS WORK? The abnormal _KRAS G12C_ protein, acts to help make cancer cells grow out of control. LUMYKRAS attaches to the protein and stops it from working, which may slow down or stop the growth of the cancer. If Läs hela dokumentet
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT LUMYKRAS 120 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 120 mg of sotorasib. Excipient with known effect Each film-coated tablet contains 108 mg of lactose (as monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). Yellow film-coated tablet, oblong-shaped (7 mm × 16 mm), debossed with “AMG” on one side and “120” on the opposite side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS LUMYKRAS as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with _KRAS G12C_ mutation and who have progressed after at least one prior line of systemic therapy. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment with LUMYKRAS must be initiated by a physician experienced in the use of anticancer medicinal products. The presence of a _KRAS G12C_ mutation must be confirmed using a validated test prior to initiation of LUMYKRAS therapy. Posology The recommended dose is 960 mg sotorasib (eight 120 mg tablets) once daily, at the same time each day. _Duration of treatment _ Treatment with LUMYKRAS is recommended until disease progression or unacceptable toxicity. _Missed doses or vomiting _ If less than 6 hours have passed since the scheduled time of dosing, the patient should take the dose as normal. If more than 6 hours have passed since the scheduled time of dosing, the patient must not take the dose. Treatment should be continued as prescribed the next day. 3 If vomiting occurs after taking LUMYKRAS, the patient must not take an additional dose on the same day, and treatment must be continued as prescribed the next day. _Dose mo Läs hela dokumentet